単純ヘルペスウィルス(TX)ワクチンの世界市場

◆英語タイトル:MarketVIEW: Herpes Simplex Virus (TX) vaccines
◆商品コード:VACZ712003
◆発行会社(リサーチ会社):VacZine Analytics
◆発行日:2017年2月
◆ページ数:※お問い合わせください。
◆レポート形式:英語 / PDF、Excel
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Executive Presentation (PDF)USD6,250 ⇒換算¥693,750見積依頼/購入/質問フォーム
PDF+ExcelUSD8,940 ⇒換算¥992,340見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はVacZine Analytics社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。VacZine Analytics社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Herpes Simplex Virus (HSV-2) is a sexually transmitted virus which is a major cause of genital herpes (GH). Although most individuals infected with HSV-2 have minimal signs of infection, the disease is life-long and in some, causes considerable emotional and physical distress. Individuals asymptomatically infected with HSV-2 can continue to transmit virus making its containment at the public health level extremely challenging.
Vaccine manufacturers have pursued the development of both prophylactic (PX) and therapeutic (TX) HSV vaccines albeit with little success to date. For therapeutic approaches a vaccine could reduce the frequency/duration of recurrences and lessen the need for long-term pharmacotherapy. Ideally the vaccine would also reduce transmission (shedding) so having a wider public health benefit. A number of Phase II HSV TX programs operated by Genocea (GEN-003), Agenus (HerpV) and COR-1 (Admedus) have already shown in a clinical setting that a HSV TX vaccine is feasible.

This MarketVIEW product is a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of a HSV therapeutic vaccine across the major Western markets to 2035. The model contains value ($ m) and volume (mio doses) predictions along with launch timeframe, pricing/penetration estimates and revenues per competitor. LO/BASE/HI target product profile (TPP) scenarios are included which examine the uptake of vaccines with differing clinical performance. A detailed review is also included on latest trends in disease epidemiology/dynamics and the competitive landscape.

【レポートの目次】

Table of Contents
Executive summary
HSV therapeutic vaccines: Commercial model: key outputs
HSV TX vaccine: total forecast value ($000s) to 2035
HSV TX vaccine: total forecast volume (000s doses) to 2035
HSV TX vaccine: LOW SCENARIO forecast value ($000s) to 2035
HSV TX vaccine: BASE SCENARIO forecast value ($000s) to 2035
HSV TX vaccine: HIGH SCENARIO forecast value ($000s) to 2035
HSV TX vaccine: forecast value ($000s) by country/region to 2035
HSV TX vaccine: forecast value ($000s) by country 5 years post-launch
HSV TX vaccine: volume (000s doses) by country/region to 2035
HSV TX: Genocea (GEN-003) $ revenues to 2035 (LO/BASE/HI)
HSV TX: Admedus (COR-1) $ revenues to 2035 (LO/BASE/HI)
HSV TX: VCL-HB01/HM01 $ revenues to 2035 (LO/BASE/HI)
Calculating TX vaccine target populations to 2035
Herpes simplex virus: Disease background
HSV – the pathogen
Life cycle and pathogenesis of HSV
HSV-1 and HSV-2 life cycles
Clinical manifestations of HSV-1 and HSV-2
Association of HSV-2 and human immunodeficiency virus
Rare, deadly outcomes of HSV infection
Clinical reactivation of HSV-1 and HSV-2
Disease burden and economic burden of HSV
Summary: HSV-1/HSV-2
Herpes simplex virus: Epidemiology
Epidemiology of HSV
Prevalence of HSV-2 infection in 2012 by WHO region
HSV-1/HSV-2 diagnosis
HSV surveillance
Epidemiology: UK
Epidemiology: US
Epidemiology: other markets

HSV-1 and HSV-2 seroprevalence studies
HSV-1 as an emerging cause of genital herpes
Herpes simplex virus: Current management strategies
Current management of genital herpes
2016 WHO recommendations for the treatment of genital HSV
Novel antivirals in development
Herpes simplex virus therapeutic vaccines: Rationale for development
Evidence that an HSV vaccine is feasible
Two approaches to HSV vaccination
The role of HSV TX vaccines
Questions and considerations on the efficacy of an HSV TX vaccine
HSV TX vaccines: past failures
Herpes simplex virus therapeutic vaccines: Overview of current research and development
HSV TX vaccines: overview
Overview: HSV TX vaccines in development
GEN-003 (Genocea)
HerpV (Agenus)
COR-1 (Admedus)
VCL-HB01/HM01 (Vical)
HSV529 (Sanofi)
HSV therapeutic vaccines: Commercial model assumptions
HSV target populations (scenario definition)
HSV vaccine: target product profiles
Commercial model assumptions: HSV vaccine
Markets included in the model
Commercial model assumptions
HSV vaccine segment analysis
HSV therapeutic vaccines: Quantifying HSV target populations
Calculating TX vaccine target populations
Bibliography
About VacZine Analytics
Disclaimer
Slide number = 95

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 単純ヘルペスウィルス(TX)ワクチンの世界市場(MarketVIEW: Herpes Simplex Virus (TX) vaccines)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆